The aim of this prospective study is to demonstrate if there is any difference in the treatment response to Sacubitril-Valsartan depending on the ventricular disfunction ethiology in patients with severe systolic disfunction heart failure.
Study Type
OBSERVATIONAL
Enrollment
100
Evaluation of the Sacubitril-Valsartan treatment effectiveness. As there are three possible doses, during the first 30 days of treatment 3 evaluations will be carried out (every 10 days) for dose titration based on safety and tolerability as well as a blood test the 30rd day of treatment. Afterwards the patient will be evaluated after 3 and 6 months of treatment with a blood test and in the final visit (6 months) an echocardiography will be carried out and the final clinical evaluation will be made.
Hospital Universitario Virgen Rocío
Seville, Spain
RECRUITINGDifference in the treatment response to Sacubitril-Valsartan depending on the ventricular dysfunction etiology.
Verify if there is any difference in the response to the treatment with Sacubitril-Valsartan depending on the ventricular dysfunction etiology, ischemic or non-ischemic (idiopathic/familiar,toxic, volume overload,etc) excluding enolic, of patients with severe systolic heart failure.
Time frame: Up to 6 months after the beginning of the Sacubitril-Valsartan treatment
Determine the microRNA genetic profile in heart failure.
Study of the microRNA genetic profile in heart failure as an indicator of the cardiac remodeling process and see its response and changes after undergoing Sacubitril-Valsartan treatment.
Time frame: Up to 6 months after the beginning of the Sacubitril-Valsartan treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.